Repatha (Evolocumab) Safety in Adolescents Ages 12, 17: What Patients and Families Need to Know

What Is Evolocumab and Why Would a 12, 17-Year-Old Need It?

Evolocumab is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors on liver cells. Blocking PCSK9 preserves those receptors, dramatically lowering circulating LDL cholesterol. Adolescents receive this drug almost exclusively for heterozygous familial hypercholesterolemia (HeFH), a genetic disorder affecting roughly 1 in 250 people that causes LDL levels often exceeding 190 mg/dL even in childhood. [1]

HeFH accelerates atherosclerosis decades earlier than in the general population. Without treatment, male patients with untreated HeFH face a 50% probability of coronary artery disease by age 50; the probability for females is approximately 30% by age 60. [2] Statin therapy is the first-line standard, but many adolescents with HeFH do not reach target LDL levels on statins alone, particularly those with baseline LDL above 250 mg/dL. [3] Evolocumab provides a second-line option with a distinct mechanism.

The FDA first approved evolocumab for adults in 2015, then extended labeling to adolescents 13 and older in 2019, and subsequently down to age 12 in 2020 for HeFH. [4] This extension was based on pediatric pharmacokinetic modeling and the HAUSER-RCT dataset.

The HAUSER-RCT: The Core Adolescent Safety and Efficacy Evidence

The HAUSER-RCT (NCT02392559) is the primary randomized controlled trial underpinning FDA approval in adolescents. Across 24 weeks, 157 adolescents ages 10, 17 with HeFH (subset ages 12, 17 constituting the majority) were randomized 2:1 to subcutaneous evolocumab 420 mg once monthly versus placebo. [5]

The mean LDL-C reduction was 38.3% with evolocumab versus a 1.5% increase in the placebo group, yielding a placebo-corrected difference of roughly 40 percentage points (P<0.001). [5] About 85% of participants were on background statin therapy, meaning these results reflect add-on benefit rather than monotherapy. 79% of the evolocumab group reached LDL-C below 130 mg/dL compared with 3% of placebo recipients. [5]

On the safety side, adverse events occurred in 68% of the evolocumab group and 65% of the placebo group, a difference that did not reach statistical significance. [5] Serious adverse events were reported in 3% of evolocumab-treated patients versus 4% of placebo recipients. No deaths occurred. [5] These numbers are consistent with adult safety data from the 27,564-patient FOURIER trial, where evolocumab showed no excess of serious adverse events over a median 2.2-year follow-up. [6]

Growth, Puberty, and Bone Development: What the Data Show

Parents and prescribers naturally ask whether blocking PCSK9, a protein expressed in multiple tissues, could disrupt growth or sexual maturation in teenagers. PCSK9 is expressed in bone, liver, adrenal glands, and neural tissue, so these concerns are biologically plausible. [7]

In HAUSER-RCT, Tanner staging was assessed at baseline and 24 weeks. No statistically significant difference in Tanner stage progression was observed between the evolocumab and placebo groups. [5] Height velocity was measured, and there was no clinically meaningful difference between arms. [5]

However, 24 weeks is a short window for evaluating skeletal or pubertal effects. The longer-term HAUSER open-label extension (OLE) followed 150 patients for an additional 72 weeks (total 96 weeks of evolocumab exposure) and reported no clinically significant changes in growth parameters, including height standard deviation scores or bone age, compared with predicted values for the participants' ages. [8] Still, 96 weeks does not capture the full adolescent growth trajectory, which can span 6 to 8 years from onset of puberty to skeletal maturity. [9]

The American Academy of Pediatrics (AAP) guidelines note that long-term PCSK9 inhibitor safety data in children remain limited and that ongoing monitoring of growth and pubertal development is warranted. [10] Prescribers should document height, weight, and Tanner stage at initiation and at each follow-up visit.

Neurological and Cognitive Safety Signals

In adult trials, a concern arose that very low LDL levels from PCSK9 inhibition might impair cognition, given that the brain uses cholesterol for myelin synthesis and synaptic function. The FOURIER cognitive substudy (EBBINGHAUS, N=1,204) found no difference in cognitive performance between evolocumab and placebo at 19 months on the Cambridge Neuropsychological Test Automated Battery (CANTAB). [11] However, adolescent brains are still developing, with prefrontal myelination continuing into the mid-twenties. [12]

No dedicated neurological or cognitive substudy exists for the adolescent HeFH population. Prescribers should ask patients and families about changes in school performance, mood, or executive function at each visit. While a causal link has not been established, this monitoring is prudent given the developmental context. [13]

Mental Health Monitoring in Adolescents

Depression and anxiety affect approximately 13 to 20% of adolescents in the general United States population. [14] Chronic disease management, including frequent injections and awareness of a hereditary condition, may add psychological burden. The HAUSER-RCT did not specifically report psychiatric adverse events as a separate category, but no signal of mood disorders was noted in the safety tables. [5]

The FDA's Prescribing Information for Repatha does not list depression or suicidality as adverse reactions, in contrast to some older lipid-modifying agents. [4] Despite this, any adolescent on evolocumab who reports mood changes, sleep disruption, or declining school performance deserves prompt mental health evaluation unrelated to but concurrent with lipid management. [10]

Injection-Site Reactions and Tolerability in Teenagers

Evolocumab is administered as a subcutaneous injection using the SureClick autoinjector (1 mL) or the Pushtronex on-body infuser (3.5 mL for the 420 mg monthly dose). In HAUSER-RCT, injection-site reactions occurred in 3.8% of the evolocumab group versus 1.9% of the placebo group. [5] Reactions were predominantly mild and transient, consisting of erythema, bruising, and local pain. None led to treatment discontinuation. [5]

Most adolescents can self-administer after a brief training session. A 2022 real-world survey of pediatric patients using PCSK9 inhibitors found that 71% preferred self-injection over clinic visits once they received hands-on device training. [15] The Pushtronex device delivers the 420 mg dose over approximately 9 minutes and may be easier for some adolescents with needle anxiety because the needle retracts automatically. [4]

Rotating injection sites between the abdomen, thigh, and upper arm reduces local reactions. Sites with bruising, scarring, or active skin conditions should be avoided. [4]

Drug Interactions and Concomitant Statin Therapy

Evolocumab is not metabolized by cytochrome P450 enzymes and does not interact with statins, ezetimibe, or most common adolescent medications. [4] Because the drug is a monoclonal antibody cleared by proteolytic degradation, the interaction profile is minimal compared with small-molecule lipid agents. [16]

In HAUSER-RCT, the most common background statins were rosuvastatin and atorvastatin, both at moderate-to-high intensity doses. [5] Adding evolocumab to these statins produced additive LDL lowering without excess myopathy or hepatotoxicity signals. [5] Creatine kinase and liver enzyme levels remained within normal limits across both groups. [5]

Ezetimibe was used as background therapy in approximately 30% of HAUSER-RCT participants, and no interaction signal emerged with that combination either. [5]

Pharmacokinetics in Adolescents Compared to Adults

Population pharmacokinetic (popPK) modeling using data from HAUSER-RCT and the open-label HAUSER pediatric study showed that evolocumab exposure (area under the curve, peak concentration) in adolescents was comparable to that in adults when the same 420 mg monthly or 140 mg biweekly dosing was applied. [17] Body weight influenced clearance modestly but not enough to require weight-based dose adjustment in this age group. [17]

Subcutaneous bioavailability is approximately 72% in adults, and no significant deviation from this value was observed in pediatric popPK analyses. [17] Half-life is approximately 11 to 17 days, consistent with other IgG2 monoclonal antibodies, meaning the drug clears over 6 to 10 weeks after discontinuation if therapy is stopped. [4]

FDA Labeling, Contraindications, and Pregnancy Considerations

The FDA Prescribing Information lists one absolute contraindication: known hypersensitivity to evolocumab or any excipient. [4] Allergic reactions, including rash, urticaria, and rare hypersensitivity events, have been reported in post-marketing surveillance for adult patients. Any teenager developing a systemic hypersensitivity reaction should discontinue evolocumab immediately and receive appropriate care. [4]

Evolocumab is classified as Pregnancy Category not assigned (post-2015 labeling), but animal studies at doses 12 times the human dose showed no fetal harm. [4] For adolescent females who are or may become pregnant, this conversation is necessary. The National Lipid Association (NLA) recommends stopping PCSK9 inhibitors upon confirmed pregnancy because the risk-benefit calculation changes when LDL targets are less pressing during gestation. [18]

Adolescent females of childbearing potential should discuss contraception and the plan for discontinuing evolocumab before conception during their prescriber visits. [18]

Monitoring Schedule Recommended for Adolescents on Evolocumab

A structured monitoring protocol reduces risk of missed adverse events. The following schedule reflects guidance from the National Lipid Association and the American College of Cardiology / American Heart Association pediatric lipid guidelines. [10, 18]

At baseline: fasting lipid panel, ALT, AST, creatine kinase, height, weight, Tanner stage, and a brief mood screen (PHQ-A for adolescents). [10]

At 4 to 8 weeks after initiation: fasting lipid panel to confirm LDL-C response and verify no unexpected enzyme elevation. [18]

Every 3 to 6 months thereafter: lipid panel, height, weight, Tanner stage, medication adherence review, and injection-site inspection if reactions are reported. [10]

Annually: comprehensive metabolic panel, a repeat discussion of growth trajectory compared with parental heights and pre-treatment growth curve, and re-evaluation of cardiovascular risk to confirm that the indication remains active. [10]

How Evolocumab Compares with Alirocumab in Adolescents

Alirocumab (Praluent) is the other approved PCSK9 inhibitor, but as of mid-2025 it does not hold FDA approval for patients under 18. [19] This makes evolocumab the only PCSK9 inhibitor with a labeled pediatric indication in the United States for adolescents with HeFH. Prescribers choosing between agents in adults consider dosing flexibility and formulary access, but in adolescents, the choice is effectively settled by labeling. [19]

Outside the United States, the European Medicines Agency (EMA) also approved evolocumab for adolescents with HeFH or homozygous familial hypercholesterolemia (HoFH) based on HAUSER-RCT data. [20] For HoFH in adolescents, where LDL levels commonly exceed 400 to 500 mg/dL, evolocumab may produce more modest reductions (approximately 20 to 30%) because these patients have severely impaired or absent LDL receptor function. [20]

Real-World Adherence and Long-Term Considerations

Medication adherence is lower in adolescents than in adults across nearly all therapeutic classes. A 2021 analysis of PCSK9 inhibitor claims data in patients under 21 found a mean proportion of days covered (PDC) of 0.61 over 12 months, below the 0.80 threshold generally accepted as adequate adherence. [21] Monthly autoinjector regimens showed higher PDC than biweekly regimens in this dataset. [21]

Cost and insurance access are the dominant adherence barriers for families. Amgen's patient assistance program (Repatha SupportPlus) covers eligible commercially insured patients at $0 copay per month and offers free drug for uninsured patients meeting income criteria. [22] Prescribers should connect families with these programs at the time of prescription rather than leaving the family to manage them independently.

Once an adolescent transitions to adult care at age 18, continuity requires explicit handoff documentation confirming the indication, current dose, last LDL-C result, and monitoring schedule. Gaps in this transition are a recognized risk period for treatment discontinuation. [10]

What Adult Cardiovascular Outcomes Data Tells Us About Long-Term Benefit

The FOURIER trial (N=27,564) is the landmark outcomes study for evolocumab in adults with established atherosclerotic cardiovascular disease (ASCVD). At a median 2.2 years of follow-up, evolocumab reduced the primary composite endpoint of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization by 15% (hazard ratio 0.85; 95% CI 0.79, 0.92; P<0.001). [6]

No comparable outcomes trial exists in adolescents because the event rate in this age group is too low for a feasible MACE trial within a reasonable time horizon. The adolescent indication is therefore justified by the surrogate endpoint of LDL-C reduction and the established causal relationship between LDL-C and atherosclerosis. The 2019 ACC/AHA guideline on primary prevention of cardiovascular disease states, "For patients with LDL-C consistently 160 mg/dL or higher, drug therapy should be considered." [23] In adolescents with HeFH whose LDL remains above this threshold despite maximally tolerated statins, evolocumab provides a guideline-concordant option. [23]

The FOURIER investigators also showed that LDL-C reductions below 20 mg/dL did not increase adverse events compared with higher achieved levels. [6] This finding provides modest reassurance for adolescent patients who achieve very low LDL levels on combined statin and evolocumab therapy.

Dosing, Administration, and Storage for Adolescent Patients

The approved dose for adolescents 12, 17 with HeFH is identical to the adult dose: 140 mg subcutaneously every 2 weeks, or 420 mg subcutaneously once monthly. [4] The 420 mg monthly dose may be administered as three consecutive 140 mg injections within 30 minutes using the autoinjector, or as a single administration using the Pushtronex on-body device. [4]

Prefilled syringes and autoinjectors should be stored refrigerated at 2, 8 degrees Celsius (36, 46 degrees Fahrenheit). Once removed from refrigeration, the product may be stored at room temperature up to 25 degrees Celsius (77 degrees Fahrenheit) for up to 30 days. [4] Adolescents who travel should pack the device in an insulated bag with a cool pack. Do not freeze, shake, or expose to direct sunlight. [4]

Before injection, the device should reach room temperature for at least 30 minutes. Injecting a cold solution increases local discomfort and may slow the injection process. [4]